OncoMatch/Blood Cancer — Myelodysplastic (MDS)/TP53
Blood Cancer — Myelodysplastic (MDS)TP53 Clinical Trials
TP53 mutations occur in approximately 10% of MDS and define very high-risk disease with poor prognosis and minimal response to standard hypomethylating agents. Multiple investigational approaches — including p53-reactivating agents (eprenetapopt) and decitabine-based regimens — have been studied without achieving regulatory approval. Trials investigate novel targeted combinations and allogeneic transplant optimization strategies for this high-unmet-need TP53-mutant population.
Top recruiting TP53 Blood Cancer — Myelodysplastic (MDS) trials
Ranked by phase and US site count.
See all trials matched to your profile →Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
St. Petersburg State Pavlov Medical University
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Peking University People's Hospital
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Heinrich-Heine University, Duesseldorf